IgA Nephropathy after Nivolumab Therapy for Postoperative Recurrence of Lung Squamous Cell Carcinoma

被引：53

作者：

Kishi, Seiji ^{[1
]}

Minato, Masanori ^{[1
]}

Saijo, Atsuro ^{[2
]}

Murakami, Naoka ^{[3
]}

Tamaki, Masanori ^{[1
]}

Matsuura, Motokazu ^{[1
]}

Murakami, Taichi ^{[1
]}

Nagai, Kojiro ^{[1
]}

Abe, Hideharu ^{[1
]}

Nishioka, Yasuhiko ^{[2
]}

Doi, Toshio ^{[1
]}

机构：

[1] Tokushima Univ, Grad Sch Biomed Sci, Dept Nephrol, Tokushima, Japan

[2] Tokushima Univ, Grad Sch Biomed Sci, Dept Resp Med & Rheumatol, Tokushima, Japan

[3] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Renal Div, Boston, MA USA

来源：

INTERNAL MEDICINE | 2018年 / 57卷 / 09期

关键词：

nivolumab; onconephrology; immune-related adverse events (irAEs); glomerular injury; IgA nephropathy; IMMUNE CHECKPOINT INHIBITORS; CANCER; MANAGEMENT; TOXICITIES; BLOCKADE; TRIAL;

D O I：

10.2169/internalmedicine.9814-17

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcinoma who was treated with nivolumab and who developed proteinuria and a worsening kidney function. A kidney biopsy revealed IgA nephropathy. After drug withdrawal, the proteinuria improved and the deterioration of the patient's renal function was halted. Although renal irAEs are considered to be rare and glomerulonephritis is not typical presentation, physicians need to pay more attention to renal irAEs and glomerular injury.

引用

页码：1259 / 1263

页数：5

共 17 条

[1] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[2] Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper [J].

Champiat, S. ;

Lambotte, O. ;

Barreau, E. ;

Belkhir, R. ;

Berdelou, A. ;

Carbonnel, F. ;

Cauquil, C. ;

Chanson, P. ;

Collins, M. ;

Durrbach, A. ;

Ederhy, S. ;

Feuillet, S. ;

Francois, H. ;

Lazarovici, J. ;

Le Pavec, J. ;

De Martin, E. ;

Mateus, C. ;

Michot, J. -M. ;

Samuel, D. ;

Soria, J. -C. ;

Robert, C. ;

Eggermont, A. ;

Marabelle, A. .

ANNALS OF ONCOLOGY, 2016, 27 (04) :559-574

[3] Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors [J].

Cortazar, Frank B. ;

Marrone, Kristen A. ;

Troxell, Megan L. ;

Ralto, Kenneth M. ;

Hoenig, Melanie P. ;

Brahmer, Julie R. ;

Le, Dung T. ;

Lipson, Evan J. ;

Glezerman, Ilya G. ;

Wolchok, Jedd ;

Cornell, Lynn D. ;

Feldman, Paul ;

Stokes, Michael B. ;

Zapata, Sarah A. ;

Hodi, F. Stephen ;

Ott, Patrick A. ;

Yamashita, Michifumi ;

Leaf, David E. .

KIDNEY INTERNATIONAL, 2016, 90 (03) :638-647

[4] Anti-CTLA4 Antibody-Induced Lupus Nephritis. [J].

Fadel, Fouad ;

El Karoui, Khalil ;

Knebelmann, Bertrand .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :211-212

[5] Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial [J].

Fellstroem, Bengt C. ;

Barratt, Jonathan ;

Cook, Heather ;

Coppo, Rosanna ;

Feehally, John ;

de Fijter, Johan W. ;

Floege, Juergen ;

Hetzel, Gerd ;

Jardine, Alan G. ;

Locatelli, Francesco ;

Maes, Bart D. ;

Mercer, Alex ;

Ortiz, Fernanda ;

Praga, Manuel ;

Sorensen, Soren S. ;

Tesar, Vladimir ;

Del Vecchio, Lucia .

LANCET, 2017, 389 (10084) :2117-2127

[6] Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors A Review [J].

Friedman, Claire F. ;

Proverbs-Singh, Tracy A. ;

Postow, Michael A. .

JAMA ONCOLOGY, 2016, 2 (10) :1346-1353

Horvat, Troy Z. ;

Adel, Nelly G. ;

Thu-Oanh Dung ;

Momtaz, Parisa ;

Postow, Michael A. ;

Callahan, Margaret K. ;

Carvajal, Richard D. ;

Dickson, Mark A. ;

D'Angelo, Sandra P. ;

Woo, Kaitlin M. ;

Panageas, Katherine S. ;

Wolchok, Jedd D. ;

Chapman, Paul B. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (28) :3193-+

[8] Renal effects of immune checkpoint inhibitors [J].

Izzedine, Hassan ;

Mateus, Christine ;

Boutros, Celine ;

Robert, Caroline ;

Rouvier, Philippe ;

Amoura, Zahir ;

Mathian, Alexis .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32 (06) :936-942

[9] Nivolumab-associated acute glomerulonephritis: a case report and literature review [J].

Jung, Kyungsuk ;

Zeng, Xu ;

Bilusic, Marijo .

BMC NEPHROLOGY, 2016, 17 :1-6

[10] Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship [J].

Molina, Julian R. ;

Yang, Piii G. ;

Cassivi, Stephen D. ;

Schild, Steven E. ;

Adjei, Alex A. .

MAYO CLINIC PROCEEDINGS, 2008, 83 (05) :584-594

← 1 2 →